An Extension of the HORIZON Protocol Evaluating the Safety of Dimebon (Latrepirdine) in Subjects With Huntington Disease (HORIZON PLUS)
This study has been completed.
Information provided by:
First received: March 10, 2010
Last updated: March 5, 2012
Last verified: March 2012
An open-label extension study of the HORIZON protocol evaluating the safety of dimebon (latrepirdine)in subjects with Huntington disease.
|Official Title:||HORIZON-Plus: An Open-Label Extension of the HORIZON Protocol (DIM20) Evaluating the Safety of Dimebon (Latrepirdine) in Subjects With Huntington Disease|
Resource links provided by NLM:
Genetics Home Reference related topics: chorea-acanthocytosis Huntington disease McLeod neuroacanthocytosis syndromeU.S. FDA Resources
Further study details as provided by Medivation, Inc.:
Contacts and Locations
No Contacts or Locations Provided